The Hepika test showed good sensitivity and specificity for invasive carcinoma, while its sensitivity for CIN3 and CIN2 was lower than that obtained by other biomarkers eligible for the HPV triage, such as cytology and p16/Ki67 dual staining (about 25% for Hepika and about 60–80% for the other biomarkers) [40,41,42,43,44,45,46,47]. The gene discussed is MKI67; the disease is invasive carcinoma.